ライフサイエンスコーパス: NGAL

1 NGAL acts as a growth and differentiation factor in mult

2 NGAL and IL-18 quantiles also predicted graft recovery u

3 NGAL blockade may be a novel therapeutic approach for th

4 NGAL can inhibit erythroid cell production, leading to a

5 NGAL depicted CIN in patients who received iodinated con

6 NGAL exerts bacteriostatic effects, which are explained

7 NGAL expression and intensity was evaluated separately.

8 NGAL expression correlated with negative hormone recepto

9 NGAL expression did not correlate with pCR in the full p

10 NGAL expression was required for MMP-9 activity and tumo

11 NGAL has subsequently been implicated in diverse cellula

12 NGAL improved the C-statistic (0.835 to 0.842) for predi

13 NGAL induced apoptosis via caspase 3 activation and up-r

14 NGAL is a glycoprotein released by damaged renal tubular

15 NGAL is a novel marker best known for its role in rapidl

16 NGAL is significantly increased in patients with myocard

17 NGAL is transcriptionally regulated by NFkappaB, and S2R

18 NGAL levels did not differ with the age, weight, height,

19 NGAL levels of >0.6 ng/mg urinary creatinine were 90% se

20 NGAL levels were strongly to moderately correlated with

21 NGAL protein expression was detected predominantly in pr

22 NGAL together with creatinine clearance plus MCP-1 was a

23 NGAL was also easily detectable in the urine of mice wit

24 NGAL was detected in 42.2% of the breast carcinomas in t

25 NGAL was easily detected in the urine in the very first

26 NGAL-knockout mice had attenuated proteinuria and improv

27 NGAL-treated animals also displayed a reduction in the n

28 ve urine biomarkers of kidney injury (IL-18, NGAL, KIM-1, L-FABP, and albumin) and five plasma biomar

29 Accordingly, NGAL-mediated iron shuttling between the extracellular a

30 In multivariate analysis, NGAL expression remained an independent prognostic facto

31 At ROC analysis, NGAL showed high sensitivity and specificity (serum NGAL

32 sterin, IL-18, kidney injury molecule-1, and NGAL concentration were predictive of DGF.

33 e reconstituted in vitro by mixing MMP-9 and NGAL in gelatinase buffers with pH values in the range o

34 levels of IL-1beta, MMP-3, MMP-8, MMP-9, and NGAL compared with the other study groups, strengthening

35 Samples were blinded and NGAL concentrations determined by enzyme-linked immunoso

36 suggests the natural ligands for C8gamma and NGAL are significantly different in size.

37 AL mRNA was rapidly induced in the cells and NGAL protein was readily detectable in the culture mediu

38 significant changes in serum creatinine and NGAL levels, and there were no cases of CIN.

39 y higher baseline concentrations of CysC and NGAL compared to patients without.

40 We determined the plasma levels of CysC and NGAL in 429 patients hospitalized for acute decompensati

41 CysC and NGAL were both predictive of 90-day mortality, with haza

42 although the relationship between ErbB2 and NGAL expression is not clear.

43 elated anemia, and the ErbB2, NF-kappaB, and NGAL pathways may serve as potential therapeutic targets

44 y of renal damage in NGAL wild-type mice and NGAL-knockout mice following induction of nephrotoxic ne

45 ed expression of mRNAs for B9, MCLP, NC, and NGAL but not for LF.

46 Lipocalin 2 (LCN2; also known as NGAL) is a secreted glycoprotein and its elevated expres

47 tic protein lipocalin 2 (LCN2; also known as NGAL).

48 e oxidation current upon the binding between NGAL and its antibody is obtained when compared to an un

49 cyclic voltammetry upon the binding between NGAL with its antibody.

50 n the fine-tuning of the interaction between NGAL and its cellular receptor or in a biochemical mecha

51 erminants underlying the interaction between NGAL and its cellular receptor remain largely unknown.

52 Tight correlations were observed between NGAL expression, renal histopathology, and urine NGAL ex

53 thesize siderophore-like molecules that bind NGAL.

54 S2R(Pgrmc1) knock-down blocked NGAL/LCN2 expression at the protein and RNA levels and d

55 l CVD risk factors and creatinine clearance, NGAL was a significant predictor of CVD mortality (hazar

56 Consistently, NGAL deficiency in genetically modified mice leads to an

57 de (NT-proBNP) and C-reactive protein (CRP), NGAL remained an independent predictor of each outcome.

58 ErbB2, NGAL, and anemia have all been associated with increased

59 The aim of this study was to evaluate NGAL as a predictor of response to NACT and to validate

60 iltration rate <60 ml/min/1.73 m(2), a first NGAL <150 ng/ml indicated a low likelihood of adverse ev

61 The first NGAL was a better predictor than peak NGAL, but similar

62 Peak NGAL was more predictive than the first NGAL, but neither added significant diagnostic utility o

63 os for CysC of 3.1 (95% CI, 2.1-4.7) and for NGAL of 1.9 (95% CI, 1.5-2.4).

64 were analysed by western blots and ELISA for NGAL expression.

65 Furthermore, NGAL could be validated as an independent prognostic fac

66 Furthermore, NGAL overexpression potently decreased angiogenesis in v

67 At 6 h, NGAL, IL-18, and L-FABP each improved the AUC from 0.72

68 elimination by Cox regression analysis, high NGAL remained an independent predictor of all-cause mort

69 Patients with high NGAL (>75th percentile) had increased risk of all-cause

70 childhood-onset SLE had significantly higher NGAL levels than did those with JIA (P < 0.0001).

71 In the HIV-transgenic mouse model of HIVAN, NGAL mRNA was abundant in dilated, microcystic segments

72 ceptor to discriminate between apo- and holo-NGAL.

73 te with pCR in the full population, however, NGAL expression and staining intensity were significantl

74 relatively high levels of lipocalin 2 (human NGAL) induced suppression of hematopoiesis in spleen and

75 ognized by a purified antibody against human NGAL as well as by a monospecific anti-human MMP-9 antib

76 recognized by antibodies specific for human NGAL or human MMP-9.

77 onformational stability of recombinant human NGAL and the solution phase binding properties of six mo

78 To determine if NGAL up-regulation is instrumental, we compared the seve

79 we compared the severity of renal damage in NGAL wild-type mice and NGAL-knockout mice following ind

80 RNA more than the corresponding increases in NGAL.

81 Interest in NGAL has been sparked by the observation that NGAL is ma

82 the calyx, whereas corresponding residues in NGAL restrict access.

83 In the iomeprol group, an early rise in NGAL was found, while serum creatinine level changes occ

84 emia and ureteral obstruction also increased NGAL and MCP-1 gene expression.

85 with a model in which S2R(Pgrmc1) increases NGAL/LCN2 levels by activating NFkappaB via EGFR.

86 Similarly, following nephritis induction, NGAL injection significantly exacerbated nephritis and d

87 ate, or physiologic saline did not influence NGAL level.

88 nal ischemia-reperfusion injury, intravenous NGAL administered before, during, or after ischemia resu

89 We found that kidney NGAL expression, as well as urine NGAL levels, were sign

90 neutrophil gelatinase-associated lipocalin (NGAL) can predict development of renal dysfunction (RD),

91 /neutrophil gelatinase-associated lipocalin (NGAL) complex is also significantly increased in AVM tis

92 neutrophil gelatinase-associated lipocalin (NGAL) detection has been developed.

93 neutrophil gelatinase-associated lipocalin (NGAL) has emerged an early marker protein, predicative o

94 neutrophil gelatinase-associated lipocalin (NGAL) in a large population of patients with ST-segment

95 Neutrophil gelatinase-associated lipocalin (NGAL) is a 25-kDa secreted acute phase protein, which is

96 neutrophil gelatinase-associated lipocalin (NGAL) is a high-quality renal biomarker of acute kidney

97 Neutrophil gelatinase-associated lipocalin (NGAL) is a novel renal biomarker that may predict WRF in

98 Neutrophil gelatinase-associated lipocalin (NGAL) is a secreted glycoprotein expressed in a variety

99 neutrophil gelatinase-associated lipocalin (NGAL) is an early biomarker for ischaemic renal injury a

100 Neutrophil gelatinase-associated lipocalin (NGAL) is an early marker of acute kidney injury (AKI).

101 neutrophil gelatinase-associated lipocalin (NGAL) is developed by the immobilization of rabbit polyg

102 Neutrophil gelatinase-associated lipocalin (NGAL) is expressed and secreted by immune cells, hepatoc

103 neutrophil gelatinase-associated lipocalin (NGAL) levels and cardiovascular and all-cause mortality

104 neutrophil gelatinase associated lipocalin (NGAL) was found to be involved in 1alpha,25(OH)2D3 and M

105 Neutrophil gelatinase-associated lipocalin (NGAL) was recently shown to be one of the maximally indu

106 neutrophil gelatinase-associated lipocalin (NGAL) were found in diseased groups compared with the he

107 neutrophil gelatinase-associated lipocalin (NGAL) were the most robust markers but were not superior

108 neutrophil gelatinase-associated lipocalin (NGAL)), which is expressed in the distal nephron, has be

109 neutrophil gelatinase-associated lipocalin (NGAL), a comparator "AKI biomarker" gene.

110 neutrophil gelatinase-associated lipocalin (NGAL), a marker of tubular injury, to determine whether

111 neutrophil gelatinase-associated lipocalin (NGAL), a novel marker of renal tubular damage, in patien

112 neutrophil gelatinase associated lipocalin (NGAL), a protein released from granules of activated neu

113 neutrophil gelatinase-associated lipocalin (NGAL), an iron-binding protein up-regulated in response

114 neutrophil gelatinase-associated lipocalin (NGAL), and monocyte chemotactic protein 1 (MCP-1).

115 neutrophil gelatinase-associated lipocalin (NGAL), because it is a small secreted polypeptide that i

116 neutrophil gelatinase-associated lipocalin (NGAL), IL-18, and kidney injury molecule-1 (KIM-1) as bi

117 neutrophil gelatinase-associated lipocalin (NGAL), interleukin-18 (IL-18), kidney injury molecule-1

118 neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1) and endothelin-1

119 neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), IL-18, and live

120 neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), IL-18, and live

121 neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), liver-type fatt

122 neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1, serum creatinine, and c

123 neutrophil gelatinase-associated lipocalin (NGAL), or plasma NGAL could identify which patients woul

124 neutrophil gelatinase-associated lipocalin (NGAL), or plasma NGAL could identify which patients woul

125 neutrophil gelatinase-associated lipocalin (NGAL), which is a new diagnostic marker of acute kidney

126 neutrophil gelatinase-associated lipocalin (NGAL).

127 neutrophil gelatinase-associated lipocalin (NGAL).

128 neutrophil gelatinase-associated lipocalin (NGAL).

129 neutrophil gelatinase-associated lipocalin (NGAL).

130 neutrophil gelatinase-associated lipocalin (NGAL); each measurement was on the day of AKI diagnosis

131 neutrophil gelatinase-associated lipocalin (NGAL, also known as LCN2) and its cellular receptor (LCN

132 neutrophil gelatinase-associated lipocalin (NGAL; also called human neutrophil lipocalin, 24p3, uter

133 neutrophil gelatinase-associated lipocalin [NGAL]) is an antimicrobial host defense factor produced

134 (neutrophil gelatinase-associated lipocalin [NGAL], interleukin [IL]-18, liver fatty acid-binding pro

135 neutrophil gelatinase-associated lipocalin, NGAL), kidney growth, and glomerulosclerosis, however, w

136 neutrophil gelatinase-associated lipocalin, NGAL.

137 , neutrophil gelatinase-associated lipocalin/NGAL, or 24p3).

138 isease (hazard ratio [per SD increase in log NGAL]=1.45 [1.22-1.72]; P<0.001 and hazard ratio=1.51 [1

139 ity and MACE compared with patients with low NGAL (log-rank test, p < 0.001).

140 elayed graft function (highest versus lowest NGAL tertile relative risk, 1.21; 95% confidence interva

141 regulation of urinary kidney injury markers (NGAL and KIM-1) and renal Interleukin-6 and Ngal mRNA ob

142 Median NGAL and IL-18 levels, but not KIM-1 levels, were statis

143 Moreover, NGAL overexpression reduced focal adhesion kinase (FAK)

144 ubular pathology, and decreased urinary NAG, NGAL, and TGF-beta1 in db/db mice.

145 CysC, but not NGAL, was found to be predictive of RD (odds ratio, 9.4;

146 rve analysis suggested that the abilities of NGAL or IL-18 to predict dialysis within 1 wk were moder

147 The ability of NGAL to protect MMP-9 activity is relevant to cartilage

148 9 activity was stabilized; in the absence of NGAL, rapid loss of MMP-9 activity occurred.

149 At 2 h, addition of NGAL increased the AUC from 0.74 to 0.85 (p < 0.0001).

150 cation improvement (>0) with the addition of NGAL was 18% (p = 0.02); the integrated discrimination i

151 By multivariate analysis, the amount of NGAL in urine at 2 h after cardiopulmonary bypass was th

152 or K562 clone (C6) expressing low amounts of NGAL.

153 The appearance of NGAL in the urine was related to the dose and duration o

154 se activity in OA SF represents a complex of NGAL and MMP-9.

155 following: urine and serum concentrations of NGAL at 2 h, and cardiopulmonary bypass time.

156 By contrast, urine concentrations of NGAL rose from a mean of 1.6 microg/L (SE 0.3) at baseli

157 osensor was investigated by the detection of NGAL in both blood serum and urine samples.

158 n, the sensor is tested for the detection of NGAL in human urine, and the results correspond well wit

159 The detection of NGAL is based on the enhancement of oxidation current on

160 current knowledge about the dual effects of NGAL as a siderophore:iron-binding protein and as a grow

161 ic antibodies stimulates local expression of NGAL, which plays a crucial role in the pathogenesis of

162 Pgrmc1) markedly regulated the expression of NGAL/LCN2 (neutrophil gelatinase-associated lipocalin/li

163 or has been constructed by immobilization of NGAL capture antibodies to electropolymerized aniline de

164 rtly abolished MART-10-induced inhibition of NGAL and cell growth in SNU308 cells.

165 wn cannot account for the internalization of NGAL by LCN2-R.

166 ed growth inhibition for CCA as knockdown of NGAL decreased Ki-67 expression in SNU308 cells and rend

167 nt of serum creatinine, and higher levels of NGAL and ET-1 were associated with a higher EVKP score (

168 xPC-3, and Capan-2) expressed high levels of NGAL but moderately to poorly differentiated PaCa cells

169 In multivariate analysis, elevated levels of NGAL or IL-18 predicted the need for dialysis after adju

170 Urinary levels of NGAL, KIM-1, and ET-1 were measured after EVKP.

171 The origin of NGAL from tubule cells was confirmed in cultured human p

172 was significantly higher in the presence of NGAL (P < 0.05).

173 In the presence of NGAL, MMP-9 activity was stabilized; in the absence of N

174 To investigate the role of NGAL in antibody-mediated nephritis, we induced nephroto

175 In this study, the role of NGAL in ischemic renal injury was explored.

176 in vitro and in vivo the functional role of NGAL in PaCa.

177 Concentrations in urine and serum of NGAL represent sensitive, specific, and highly predictiv

178 g creatinine, sensitivity and specificity of NGAL for detecting acute injury were 0.900 (95% CI, 0.73

179 These data show that marked upregulation of NGAL accompanies HIVAN and support further study of uNGA

180 Taken together, upregulation of NGAL by ErbB2 through NF-kappaB activation is involved i

181 The marked upregulation of NGAL mRNA and protein levels in the early postischemic m

182 For concentration in urine of NGAL at 2 h, the area under the receiver-operating chara

183 However, the prognostic value of NGAL has never been studied in patients with myocardial

184 These pleiotropic functions mainly rely on NGAL's siderophore-mediated iron transport properties.

185 Finally, MIAPaCa-2 cells overexpressing NGAL reduced tumor volume (P = 0.012), local and distant

186 Compared with K562 cells, overexpressing NGAL in K562 led to a higher apoptosis rate and an atrop

187 In particular, NGAL is emerging as an excellent biomarker in the urine

188 surement of urinary biomarkers, particularly NGAL in combination with functional perfusion parameters

189 Peak NGAL was more predictive than the first NGAL, but neithe

190 first NGAL was a better predictor than peak NGAL, but similar to the first creatinine (areas under t

191 Plasma NGAL is a significant predictor of mortality and CVD in

192 Plasma NGAL levels were measured using a time-resolved immunofl

193 Plasma NGAL predicts mortality in patients with heart failure,

194 Plasma NGAL was not superior to creatinine for the prediction o

195 Plasma NGAL, estimated glomerular filtration rate (eGFR), and c

196 95% confidence interval=1.3-9.1), and plasma NGAL (odds ratio=7.7, 95% confidence interval=2.6-22.5).

197 clusion, urine IL-18, urine NGAL, and plasma NGAL associate with subsequent AKI and poor outcomes amo

198 highest quintiles of urine IL-18 and plasma NGAL associated with 6.8-fold and 5-fold higher odds of

199 Elevated urine IL-18 and urine and plasma NGAL levels associated with longer length of hospital st

200 Urine IL-18 and urine and plasma NGAL levels peaked within 6 hours after surgery.

201 Urine IL-18 and plasma NGAL significantly improved risk prediction over the cli

202 Urine IL-18 and plasma NGAL significantly improved the AUC to 0.76 and 0.75, re

203 High plasma NGAL independently predicts all-cause mortality and MACE

204 w cystatin C (median cut-off), higher plasma NGAL levels were independently associated with an increa

205 Higher plasma NGAL levels were independently associated with an increa

206 We measured plasma NGAL levels in 1,393 Rancho Bernardo Study participants

207 was 11.2 (7.7-16.2) mg/L, and median plasma NGAL was 85 (60-123) ng/mL.

208 , urine IL-18 and urine NGAL, but not plasma NGAL, associate with subsequent AKI and poor outcomes am

209 The use of plasma NGAL to diagnose acute kidney injury in AHF cannot be re

210 inase-associated lipocalin (NGAL), or plasma NGAL could identify which patients would develop AKI and

211 inase-associated lipocalin (NGAL), or plasma NGAL could identify which patients would develop AKI and

212 The primary outcome was whether plasma NGAL could predict the development of WRF, defined as a

213 d with the clinical model alone, with plasma NGAL performing the best (category-free net reclassifica

214 In univariate survival analysis, positive NGAL expression and strong staining intensity correlated

215 including lysozyme, siderocalin (the protein NGAL), which inhibits bacterial growth by binding iron-c

216 latinase in OA SF comigrated with a purified NGAL-MMP-9 complex.

217 Putative NGAL ligands, including neutrophil chemotactic agents su

218 Recently, NGAL has been proposed as an early biomarker in pancreat

219 enous administration of purified recombinant NGAL in mice resulted in a rapid uptake of the protein p

220 ase 1, and the inhibitors partially restored NGAL levels.

221 Serum NGAL is a highly sensitive but nonspecific predictor of

222 Serum NGAL was measured during the first 24 hrs of admission t

223 Serum NGAL was significantly increased in critically ill child

224 Urine NGAL and serum NGAL (sNGAL) were assessed at 2, 6, 24, and 48 hours aft

225 There was a significant difference in serum NGAL between healthy children (median 80 ng/mL, interqua

226 Further validation of serum NGAL as a biomarker of acute kidney injury in this popul

227 owed high sensitivity and specificity (serum NGAL: area under the curve, 0.995; 95% confidence interv

228 Lipocalin 2 (siderocalin, NGAL, 24p3), a siderophore-binding antimicrobial protein

229 untreated tissue microarray showed specific NGAL staining in resected PaCa specimens (P = 0.0167).

230 Stable NGAL overexpression (MIAPaCa-2 and PANC-1) significantly

231 Stable NGAL overexpression or underexpression had no effect on

232 In addition, strong NGAL expression correlated with higher pCR rates in node

233 The results show that in low-risk subgroups, NGAL was found to be a predictive marker for pCR after N

234 Our data demonstrate that NGAL is capable of protecting MMP-9 from degradation in

235 New data have demonstrated that NGAL is also stored in granules of mature neutrophils, a

236 The results indicate that NGAL may represent a novel therapeutic intervention in i

237 The results indicate that NGAL may represent an early, sensitive, noninvasive urin

238 GAL has been sparked by the observation that NGAL is massively upregulated after renal tubular injury

239 We therefore propose that NGAL participates in the antibacterial iron depletion st

240 Here we report that NGAL tightly binds bacterial catecholate-type ferric sid

241 Regression analysis showed that NGAL independently predicted CIN.

242 In our previous work we showed that NGAL, a protein involved in the regulation of proliferat

243 re neutrophils, and recent data suggest that NGAL may also be involved in the development of atherosc

244 Collectively, our results suggest that NGAL reduces adhesion/invasion partly by suppressing FAK

245 The NGAL-MMP-9 complex was reconstituted in vitro in gelatin

246 in the absence of renal injury, induced the NGAL gene, but not MCP-1, suggesting the possibility of

247 ll as Akt and ERK inhibitors, suppressed the NGAL/LCN2 RNA and protein levels.

248 Thus, NGAL is a potential suppressor of invasion and angiogene

249 , we show that ErbB2 overexpression leads to NGAL upregulation, which is dependent on nuclear factor-

250 (50-500ngmL(-1)) and high specificity toward NGAL detection from small samples (10muL).

251 PANC-1 and MIAPaCa-2) expressed undetectable NGAL levels.

252 Urinary NGAL is a promising potential biomarker of childhood-ons

253 Urinary NGAL was assessed in spot urine of 182 outpatient renal

254 Urinary NGAL was measured by immunoblot, N-acetyl-beta-d-glucosa

255 Urinary NGAL, at respective cut-off, accurately discriminates ac

256 fidence interval [CI]: 0.868, 0.992; urinary NGAL: area under the curve, 0.992; 95% CI: 0.925, 1.000)

257 o determine the relationship between urinary NGAL excretion and SLE disease activity or damage, with

258 In contrast, urinary NGAL did not correlate with proteinuria in human or in m

259 cohort to more accurately delineate urinary NGAL excretion in relation to the diverse SLE phenotypes

260 Here, we demonstrate urinary NGAL to allow for differential diagnosis of AKI, accurat

261 ipient characteristics, higher donor urinary NGAL concentrations associated with recipient delayed gr

262 al function demonstrated that higher urinary NGAL and L-FABP concentrations associated with slightly

263 ry had a significantly elevated mean urinary NGAL level compared with the other kidney function group

264 th stable allograft function, median urinary NGAL concentration was 7.8 ng/mL (interquartile range, 3

265 With a cut-off at 100 ng/mL, urinary NGAL accurately predicted acute rejection as underlying

266 A single measurement of urinary NGAL helps to distinguish acute injury from normal funct

267 We found that expression of urinary NGAL was much higher in patients with biopsy-proven HIVA

268 As a readily available parameter, urinary NGAL may guide differential diagnosis and initial therap

269 In multiple logistic regression, urinary NGAL level was highly predictive of clinical outcomes, i

270 In acute allograft rejection, urinary NGAL concentration was 339 ng/mL (165-499 ng/mL), and in

271 In summary, urinary NGAL and IL-18 are early, noninvasive, accurate predicto

272 Urine NGAL <20 ng/mL and sNGAL <179 ng/mL at 6 hours are relia

273 Urine NGAL and serum NGAL (sNGAL) were assessed at 2, 6, 24, a

274 Urine NGAL significantly increased in AKI patients at 2 h afte

275 Urine NGAL, IL-18, L-FABP, and KIM-1 are sequential predictive

276 In conclusion, urine IL-18, urine NGAL, and plasma NGAL associate with subsequent AKI and

277 e highest quintiles of urine IL-18 and urine NGAL associated with 6.9- and 4.1-fold higher odds of AK

278 expression, renal histopathology, and urine NGAL excretion.

279 The accuracy of urine IL-18 and urine NGAL for diagnosis of severe AKI was moderate, with area

280 Elevated urine IL-18 and urine NGAL levels associated with longer hospital stay, longer

281 he first postoperative urine IL-18 and urine NGAL levels strongly associated with severe AKI.

282 In conclusion, urine IL-18 and urine NGAL, but not plasma NGAL, associate with subsequent AKI

283 hat kidney NGAL expression, as well as urine NGAL levels, were significantly increased in mice with n

284 duced AKI occurred at 6 hours for both urine NGAL (>/=20 ng/mL; 97% negative predictive value and 27%

285 nclusion, among prevalent KTRs, higher urine NGAL, KIM-1, and IL-18 levels independently and differen

286 Each log increase in urine NGAL/creatinine independently associated with a 24% grea

287 ents (validation set), no patient with urine NGAL <20 ng/mL or sNGAL <179 ng/mL at 6 hours developed

288 redictor of response to NACT and to validate NGAL as a prognostic factor for clinical outcome in pati

289 Moreover, when NGAL was entered in the multivariable risk prediction mo

290 subjected to in vitro ischemic injury, where NGAL mRNA was rapidly induced in the cells and NGAL prot

291 stly improved the prediction of DGF, whereas NGAL, serum creatinine, and the creatinine reduction rat

292 We undertook this study to determine whether NGAL is instrumental in the pathogenesis of nephritis, i

293 This study sought to determine whether NGAL is superior to creatinine for prediction and/or pro

294 ay represent an important mechanism by which NGAL may contribute to the loss of cartilage matrix prot

295 at day 3 did not provide any benefit; while NGAL is also associated with short-term mortality, it fa

296 n and disease was obtained and compared with NGAL levels (ng/mg of urinary creatinine) measured by en

297 intrinsically disordered and interacts with NGAL preferentially in its apo state to form a fuzzy com

298 Participants with NGAL and NT-proBNP above the median had increased risk o

299 The 125-kDa urinary MMP-9 x NGAL complex was recognized by a purified antibody again

300 rates with purified human neutrophil MMP-9 x NGAL complex.

301 In addition, the complex of MMP-9 x NGAL could be reconstituted in vitro by mixing MMP-9 and